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Clinical immunotherapy trials like dendritic cell-based vaccinations are hampered by the tumor’s offensive repertoire that
suppresses the incoming effector cells. Regulatory T cells are instrumental in suppressing the function of cytotoxic T cells. We
studied the effect of low-dose cyclophosphamide on the suppressive function of regulatory T cells and investigated if the success
rate of dendritic cell immunotherapy could be improved. For this, mesothelioma tumor-bearing mice were treated with dendritic
cell-based immunotherapy alone or in combination with low-dose of cyclophosphamide. Proportions of regulatory T cells and
the cytotoxic T cell functions at different stages of disease were analyzed. We found that low-dose cyclophosphamide induced
beneficial immunomodulatory effects by preventing the induction of Tregs, and as a consequence, cytotoxic T cell function was
no longer affected. Addition of cyclophosphamide improved immunotherapy leading to an increased median and overall survival.
Future studies are needed to address the usefulness of this combination treatment for mesothelioma patients.
1. Introduction
Malignant mesothelioma (MM) is a cancer arising from
mesothelial cells that lines the body’s serous cavities (pleural,
pericardial, and peritoneal) and the internal organs and
is characterized by poor prognosis [1]. Chemotherapy or
surgical treatments result in only limited improvements
in response and survival. Novel therapeutic strategies are
therefore needed. Immunotherapy is a promising but also
challenging approach in the treatment of cancer.
Dendritic cells (DCs) are highly mobile antigen-
presenting cells, capable of instructing and controlling the
activation of NK cells, NKT cells, and B and T lymphocytes
[2–4]. Previously we showed that DC-based immunotherapy
in a murine MM model leads to protective immunity as
well as regression of established tumors [5]. Currently we
are investigating DC-based immunotherapy in MM patients.
Although DC-vaccines are well tolerated by patients, further
optimization is necessary to exploit the full potential of this
therapeutic strategy [6].
It is becoming evident that immune suppression plays
a crucial role in tumor progressing. Tumors secrete several
mediators to recruit and/or activate suppressive cells. Regu-
latory T cells (Tregs) are prominent cells in this suppressive
environment. These cells are instrumental in allowing a
growing cancer to evade immunological attack by impairing
T cell function [7]. Elevated levels of Tregs have been
reported in many tumors and their presence predicts for
poor survival. We have demonstrated previously the presence
of Tregs within the tumors of MM patients [8]. It has also
been described that Tregs are increased in the peripheral
blood [9] and pleural effusions [10] of these patients.
Recent clinical studies have shown that low-dose
cyclophosphamide (CTX) induces beneficial immunomod-
ulatory effects in the context of active or adoptive
immunotherapy [11–21]. CTX is widely used to treat various
types of malignancies and some autoimmune disorders. It
displays either immunosuppressive or immunopotentiating
effects, depending on the dosage and the timing of drug
administration [22]. Although the mechanisms underlying
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these modulations are not fully understood, low-dose CTX
might prevent the development and functionality of the
Tregs [23–27].
Van der Most et al. reported that CTX enhances the effec-
tiveness of gemcitabine treatment in murine mesothelioma
by reducing the amount of Tregs [28, 29]. Thereby they
underline the immunogenic role of Tregs in the suppression
of activated target cells. On the other hand, Jackaman et
al. recently stated that Tregs are no potent regulators of
antimesothelioma immunity in their murine model and that
targeting of these cells will not improve results [30]. Taken
together, the role of Tregs in mesothelioma is controversial
and whether these cells will influence the outcome of
immunotherapy is still unclear.
Here we investigated the effect of CTX on immuno-
suppression and the combination of CTX and DC-based
immunotherapy was studied in a murine MM model.
We found that CTX reduced the levels of Tregs and
this induced beneficial immunomodulatory effects in the
context of DC-based immunotherapy. These results antic-
ipate that antitumor immune responses elicited by DC-
based immunotherapy in humans might be improved by
simultaneously depleting Tregs using low-dose CTX.
2. Methods
2.1. Animals and Cell Lines. Female 6–10 week old BALB/c
(H-2d) mice (Harlan, Zeist, The Netherlands) were housed
under pathogen-free conditions at the animal care facility
of the Erasmus MC, Rotterdam. Experiments were approved
by the local Ethical Committee for Animal Welfare and
complied to the Guidelines for the Welfare of Animals in
Experimental Neoplasia by the United Kingdom Coordi-
nating Committee on Cancer Research (UKCCCR) and by
the Code of Practice of the Dutch Veterinarian Inspection.
The AB1 cell line, a mouse mesothelioma cell line, was
kindly provided by Professor Bruce W.S. Robinson of the
Queen Elizabeth II Medical Centre, Nedlands, Australia. The
cell line was derived from tumors induced by Wittenoom
Gorge crocidolite asbestos injected intraperitoneally into a
BALB/c mouse [31]. Cells were cultured in RPMI 1640
medium containing 25 mM HEPES, Glutamax, 50 μg/ml
gentamicin, and 5% (v/v) fetal bovine serum (FBS) (all
obtained from GIBCO/Invitrogen, Breda, The Netherlands)
in a humidified atmosphere at 37◦C and 5% CO2, in air. AB1
cells were passaged once or twice a week to a new flask by
treatment with 0.05% trypsin, 0.53 mM EDTA in phosphate
buffered saline (PBS, all GIBCO/Invitrogen). The cell line
was regularly tested and remained negative for mycoplasma
contamination.
2.2. Reagents. Cyclophosphamide ([CTX], the generic name
for Endoxan) was purchased from Baxter B.V., Utrecht, The
Netherlands. A stock solution was prepared by dissolving 1
gram into 50 ml of PBS. It was further diluted in drinking
water at a concentration of 0.13 mg/ml.
Every 4 days bottles were carefully examined (volume
was determined) and replaced with fresh bottles containing
100 ml of drinking water or CTX-containing water. No
changes in the drinking pattern of mice were observed
between tumor-bearing mice with normal water or with
CTX-containing drinking water (+/−3 ml per day per
mouse). This equals approximately 20 mg CTX/kg body
weight/day and is considered as a low-dose. Dehydration,
being one of the points for signs of illness, was routinely
checked. No signs of dehydration were observed during
experiments except for a few cases with ill health or overt
tumor growth.
2.3. Source of Tumor Antigen Derived from AB1 Tumor. AB1
cell line-derived tumor lysate was prepared from 50 × 106
cells suspended per ml PBS. The cell suspension was frozen
in liquid nitrogen and disrupted by four cycles of freeze-
thawing followed by sonication for 4 × 10 seconds with an
amplitude of 10 microns, using a Soniprep 150 ultrasonic
disintegrator equipped with a microtip (Sanyo Gallenkamp
BV, Breda, The Netherlands) on ice. Cell lysate was aliquoted
and stored at −80◦C.
2.4. Culture Conditions of Bone Marrow-Derived DC Used
for Vaccination. DCs were generated with only minor adap-
tations from a previously described protocol by Lutz [32].
After flushing femurs and tibias and red blood cell lysis,
resulting bone marrow cells (2 × 106) were seeded in 100-
mm Petri dishes (day 0) and cultured in 10 ml DC Cul-
ture Medium [DC-CM]: RPMI 1640 containing glutamax-
I (GIBCO/Invitrogen) supplemented with 5% (v/v) FBS,
50 μM β-mercaptoethanol (Sigma-Aldrich), 50 μg/ml gen-
tamicin (Invitrogen), and 20 ng/ml recombinant murine
granulocyte macrophage-colony-stimulating factor [GM-
CSF, kindly provided by Professor K. Thielemans, Free
University Brussels, Belgium]. Cells were cultured at 37◦C
in a humidified atmosphere at 5% CO2 , in air. At day
3, 10 ml of fresh DC-CM was added. On day 6, 10 ml of
each plate was replaced with 10 ml of fresh DC-CM. After
8 days of culture, AB1 cell lysate was added to the DC
cultures, to the equivalent of three AB1 cell-equivalents per
DC. After 8 hours, 100 μg/ml LPS (E. coli 026:B6, Sigma-
Aldrich) was added to the culture to allow complete matu-
ration while incubated overnight. The next day, DCs were
harvested by gentle pipetting and purified by Lympholyte-
Mammal (Cedarlane, Hornby, ON, Canada) density gradient
centrifugation, the interphase washed three times in PBS and
resuspended at a concentration of 1×106 viable cells in 500 μl
PBS. The quality of the DC preparation was determined by
cell-counting, morphologic analysis and cell surface marker
expression by flow cytometry, as previously described [5].
DCs (1 × 106) were delivered into the peritoneal cavity of
BALB/c mice; control mice received 500 μl PBS.
2.5. Treatment with Tumor Lysate-Pulsed DCs and Cyclophos-
phamide on Outcome. Initial experiments were performed
to determine the optimal concentration of CTX necessary
to reduce Tregs in vivo. Continuous administration via
the drinking water of low concentrations (“metronomic”)
CTX had our preference because a single administration
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of a higher dose or multiple administrations i.p. engenders
worse life expectancy as a consequence of peritoneal damage
caused by the needle. Approximately 20 mg CTX/kg body
weight/day in the drinking water of mice was the optimal
concentration for further studies in mice, concentrations
below 100 mg/kg are considered as a low dose. No effect on
feeding, body weight, and physical well-being or other side
effects were observed at this concentration.
On day 0, BALB/c mice (4 groups each consisting of 6
mice) were inoculated intraperitoneally with 0.5 × 106 AB1
tumor cells in 500 μl PBS. On day 12, 12 mice (2 groups)
were vaccinated with 1× 106 LPS-matured DCs pulsed with
AB1 tumor cell line lysate in 500 μl PBS. From day 3 till day
10 and/or day 14 till day 21 mice were given drinking water
supplemented with 0.13 mg/ml CTX. Mice were examined
daily for evidence of ill health or overt tumor growth.
Mice were killed if profoundly ill, according to UKCCCR
regulations, and were scored as a death in survival analysis.
All mice underwent extensive autopsy.
2.6. Immunohistology on Tumor Biopsies. Tumor biopsies
were embedded in Tissue-Tek II optimum cutting temper-
ature medium (Miles, Naperville, IL, USA), snap-frozen,
and stored at −80◦C. Tissue sections (6 μm) were cut on
an HM-560 cryostat (Microm, Heidelberg, Germany) and
immunostaining was carried out using a rat antimouse
Foxp3 antibody (eBioscience [#14-5773], San Diego, CA,
USA). Binding of antibody was detected using alkaline
phosphatase- (AP-) conjugated goat antirat (Sigma-Aldrich
Chemie B.V.). Naphtol-AS-MX-phosphate (0.30 mg·mL−1;
Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands)
and new fuchsine (160 mg·mL−1 in 2 M HCl; Chroma-
Gesellschaft, Ko¨ngen, Germany) were used as substrate.
The specificity was checked using a protein concentration-
matched nonrelevant rat antibody and PBS. Double staining
of Foxp3 and CD8 was performed using the AP-conjugated
goat antirat followed by rabbit antiphycoerythrin (AbD
Serotec, Du¨sseldorf, Germany) followed by incubation with
horseradish peroxidase- (HRP-) conjugated swine antirabbit.
Naphtol-AS-MX-phosphate and 1 mM Fast Blue substrate
were used as substrate for AP, and NovaRed was used as sub-
strate for HRP, according to the manufacturer’s instructions
(Vector, Burlingame, CA, USA). Foxp3 and phycoerythrin-
labeled antimouse CD8 (BD Biosciences, San Jose, CA, USA)
were both used at a dilution of 1 : 10. Signals were captured
on a Leica microscope (Leica Microsystems B.V., Rijswijk,
The Netherlands).
2.7. Preparation of Lymphocytes from Lymphoid Organs or
Blood. Lymphocytes were collected from the spleens, lymph
nodes, and blood of mice from each group. Briefly, spleens
and lymph nodes were aseptically removed and mechanically
dispersed in cold PBS. Cells suspensions were filtered
through a 100 μm nylon mesh cell strainer (BD Biosciences,
Bedford, MA, USA). Resulting suspensions and blood were
depleted of erythrocytes by density gradient centrifugation,
washed twice with PBS +2% BSA, and resuspended at a
concentration of 1×106 cells/ml for flow cytometric analysis.
2.8. Flow Cytometry. The following antimouse antibodies
were used: fluorescein isothiocyanate- (FITC-) conjugated
anti-CD4 (1 : 800), anti-CD19 (1 : 200), phycoerythrin- (PE-
)-conjugated anti-CD3 (1 : 25), anti-CD25 (1 : 200) (all
from BD Biosciences), allophycocyanin- (APC)conjugated
anti-Foxp3 (1 : 25) (eBioscience), and appropriate isotype-
matched controls.
For cell surface marker staining, cells were washed with
FACS-wash (0.05% NaN3, 2% BSA in PBS) and Fcγ II/III
receptor blocking was performed using antimouse 2.4G2
antibody (1 : 100; kindly provided by L. Boon, Bioceros,
Utrecht, The Netherlands) for 15 minutes on ice. After
the blocking procedure, properly diluted antibodies for cell
surface staining were added into each sample and placed on
ice for 30 minutes protected from light. After two additional
washes with FACS-wash, Fix/Perm buffer (eBiosience) was
added and cells were incubated for 1 hour at 4◦C in the
dark. Cells were washed twice with Perm buffer. Intracel-
lular staining was performed for Foxp3 according to the
manufacturer’s instructions (eBioscience). After blocking for
15 minutes with blocking antibody 2.4G2, properly diluted
APC-conjugated Foxp3 antibody in Perm buffer was added
and incubated for 30 minutes on ice protected from light.
After washing the cells twice with Perm buffer, cells were
washed with FACS-wash and measured. Data acquisition was
performed by flow cytometry (LSR II; BD Biosciences) and
data analysis was performed with FlowJo software (Tree Star,
Inc.).
2.9. Coculture of Tregs and Activated Splenocytes. Splenocytes
obtained from tumor-bearing mice were stained for CD3,
CD4, CD8, and CD25. Four colour sample sorting was done
on a FACS ARIA (BD Biosciences). Tregs were defined as
CD3+CD4+CD25+bright cells and sorted with a purity >90%
as determined by intracellular staining on Foxp3 expression.
Splenocytes of DC-treated mice were cocultured with sorted
Treg cells at different ratios. Splenocytes were restimulated
for 4 hours using anti-CD3 and stained with mAbs directed
against CD3, CD8, intracellular Granzyme B, and IFN-γ.
2.10. Statistical Analysis. Data are expressed as mean ± SD.
Comparisons between groups were made using the Mann-
Whitney U-test for independent samples. A two-tailed P-
value < .05 was considered significant. Data presented as
a percentage of tumor-free animals were analyzed with
Kaplan-Meier survival curves, using the log-rank test to
determine statistical significance.
3. Results
3.1. Regulatory T Cells in the Mouse Mesothelioma Model.
The mesothelioma mouse model described in our pre-
vious study was used to examine the presence of
CD4+CD25+Foxp3+ T cells in tumor progression [8].
In this protocol, BALB/c mice were intraperitoneally (i.p.)
injected with a lethal dose of 0.5 × 106 AB1 tumor cells
or 500 μl PBS as control. First signs of terminal illness
(typically formation of ascites, ruffled hair, or marked loss of
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condition) appeared between 20 days and 30 days in tumor
cell inoculated mice. Mice were sacrificed and subjected to
extensive autopsy. All tumor inoculated mice showed solid
tumor formation within the peritoneal cavity. The nature
of these solid tumors varied from small nodules spreading
throughout the mesentery and peritoneal lining to a single
large mass. Tumor tissue, blood, spleen, and lymph nodes
were collected from tumor-bearing mice for further analyses
at day 10 or at first signs of terminal illness. No tissue
abnormalities or formation of tumors could be detected in
naive (PBS treated) mice.
The presence of Tregs in mesothelioma tissue sections
at day 10 was analyzed by immunohistochemistry for the
phenotypic evidence of the transcription factor Foxp3, a
hallmark of naturally arising CD4+CD25+ Treg cells [33–
37]. Stainings confirmed that mouse tumor tissue obtained
from AB1 inoculated mice contained significant amounts
of Foxp3+ regulatory T cells, consisting with previous find-
ings in human mesothelioma tissue [8]. Foxp3-expressing
cells were located in the proximity of the tumor areas
(Figure 1(a)). Double staining showed that the presence
of these cells was occasionally in the vicinity of CD8+T
cells, suggesting their possible direct suppressive role in
antitumoral responses (Figure 1(b)).
We then examined the blood and peripheral lymphoid
organs for the presence of Tregs, determined by CD4, CD25,
and Foxp3 positive expression using flow cytometry. In
peripheral blood of control mice, the mean proportion
of Treg cells was 4.9% of all CD4+ T cells. The percent-
age increased in the blood to 6.1% ten days after the
inoculation of AB1 tumor cells (Figure 1(c)). Also the
CD4+CD25+Foxp3+ Tregs were increased in the lymph nodes
from 8.9% to 11.5% of the total CD4+ T cell population
in tumor-bearing mice (Figure 1(d)). In the splenocytes
from tumor-inoculated mice, the presence of Foxp3+ Tregs
increased to 11% compared to 9% in the control group
treated with PBS alone (data not shown).
To determine the impact of a growing tumor on Tregs,
the percentage of Foxp3+ T cells in the draining lymph
nodes was measured. Total weight of excised tumor tissue
and the percentage of Tregs in the draining lymph nodes of
corresponding mice are depicted in Figure 1(e). At ten days
after AB1 inoculation (n = 5), the weight of the total tumor
mass collected varied from 0.1 gram to 1 gram, or larger (1.5
to 2.1 gram) when mice showed evidence of ill health or overt
tumor growth (n = 3).
In conclusion, Tregs were found within the tumor area
and increased proportions of Tregs were found in the tumor-
bearing mice. Moreover we show a significant increase in the
proportion of Tregs that correlates with tumor burden (P =
.0039).
3.2. Reduction of Tregs Improves Cytotoxic T Cell Function
In Vivo. To demonstrate that cytotoxic T cell function is
inhibited by Tregs, the intracellular expression of granzyme
B and IFN-γ in activated CD8+ T cells was measured.
Tregs from tumor-bearing mice were isolated from spleen.
These CD4+CD25+ T cells were then added in different
ratios to the activated splenocytes isolated from DC-treated
mice. Intracellular granzyme B expression by CD8+ T cells
decreased in the fractions containing high amounts of
CD4+CD25+ T cells. The same was observed for the IFN-γ
expression (Figure 2). When CD4+CD25+ T cells are present
in a ratio higher than 1 : 100, the function of CD8+ T cell is
impaired.
Taken together, these data provide evidence that the
addition of Tregs leads to impaired CD8 T cell activation.
3.3. Effects of Low-Dose Cyclophosphamide on the T and B Cell
Populations. To examine the immunomodulating effects of
CTX on Tregs, BALB/c mice were inoculated i.p. with 0.5 ×
106 AB1 mesothelioma tumor cells and given drinking water
with or without CTX. After 10 days peripheral blood and
spleen were analyzed. Metronomic CTX treatment resulted
in a significant decrease in the proportions of CD19+ B cells
and an increase of CD3+ T cells (Figures 3(a) and 3(b)), in
agreement with reports by others [13]. In contrast to the
significant increase in the proportions of total CD3+ T cells,
we observed a significant reduction in the fractions of Foxp3+
T cells (Figures 3(a) and 3(b)).
In summary, these data show that metronomic adminis-
tration of low-dose CTX has a strong immune-modulating
effect in vivo, causing a shift in ratio between CD19+/CD3+
cells. Addition of CTX to drinking water of mice leads to a
significant increase in the proportion of CD3+ T cells in the
peripheral blood and the spleen, whereas the proportion of
Tregs is reduced.
3.4. CTX Improves Suboptimal Dc-Based Immunotherapy.
Next, we then investigated if combining CTX and DC
vaccination enhanced the efficacy of the DC treatment as an
antitumor treatment. In contrast to optimal DC-treatment
protocols (as described by Hegmans et al. [5]), DCs are given
at a relative late time point (day 12) in order to achieve
suboptimal survival of DC-treated mice. Twelve days after
i.p. tumor cell inoculation, mice were vaccinated with 1×106
LPS-matured DCs pulsed with AB1 tumor lysate. Mice that
received CTX had an increased survival, as seen in our earlier
experiments, compared to untreated mice.
When mice were given drinking water supplemented
with 0.13 mg/ml CTX from day 3 till day 10 and day 14 till
day 21, an increased survival was measured. However, the
combination of DC-based immunotherapy and CTX admin-
istration significantly improved survival compared to DC-
based immunotherapy (P < .0035) or CTX administration
alone (P < .0056) (Figure 4).
Therefore, we conclude that CTX is a powerful tool to
optimize suboptimal DC-based immunotherapy. Although
CTX alone also improves survival, the combination of both
was significantly better.
3.5. Long-Term Administration of CTX Improves Survival
Compared to Pre- or Postlmmunotherapy Treatment. It has
been reported that the timing of CTX administration is
critical [38, 39], therefore we investigated the consequences
of administration at different time points. To evaluate the
effect of timing of CTX administration, mice were divided
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Figure 1: Increase in the proportion of regulatory T cells in a murine model for mesothelioma. (a) Left: The transcription factor Foxp3, a
hallmark of naturally arising CD4+CD25+ Tregs, was expressed inside the tumor (red staining). Cells were counterstained with haematoxylin.
[Magnification 200×] Right: A higher magnification (400×) shows the appearance of Foxp3+ cells as indicated by arrows. (b) Tregs (blue
staining) were occasionally present in the near vicinity of CD8+ cells (red staining) [Magnification 1000×]. (c) and (d) Percentage of Tregs
(defined as CD4+CD25+Foxp3+ cells) from total CD4+ T cells in the peripheral blood and draining lymph nodes is significantly higher at
day 10 in tumor-bearing mice compared to healthy mice as observed by flow cytometry. (e) A positive correlation was found between the
total tumor weight and the percentage of Tregs, measured in the lymph nodes of tumor-bearing mice. Five mice were euthanized at day 10
(tumor weight varied from 0.1 gram to 1 gram) and three mice at stage with ill health (tumor weight 1.5 to 2.1 gram). Correlation coefficient
of the trend line (R-squared) is 0.780 (P value is .0039).
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Figure 2: Tregs inhibit CTL function in vitro. (a) Activated splenocytes from DC-treated mice were cocultured with CD4+CD25+Foxp3+
cells (purified from tumor-bearing mice) in different ratios. The percentage of intracellular IFN-γ of CD8+ cells was measured using flow
cytometry. And (b) the percentage of intracellular IFN-γ and granzyme B expression was measured using FACS. A reduction in the IFN-γ
and granzyme B expression was found especially in those fractions where increasing doses of Treg were added to the CD8+ T cells.
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Figure 3: CTX influences lymphocyte subsets in peripheral blood and draining lymph nodes of tumor-bearing mice. (a) The percentage of
CD19+ cells was significantly decreased (P < .05) in CTX-treated tumor-bearing mice. CD3+ cells were significantly increased (P = .0325)
in the peripheral blood of CTX-treated tumor-bearing mice compared to untreated tumor-bearing mice. (b) CD19+ cells were significantly
decreased (P < .05) while CD3+ cells were significantly increased (P < .05), while the percentage of CD4+CD25+Foxp3+ cells was significantly
decreased (P < .05) in the splenocytes of CTX-treated mice compared to untreated tumor-bearing mice.
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Figure 4: CTX combined with DC-based immunotherapy prolongs
survival. Kaplan-Meier survival plot showing the effect of the
combination of CTX and DC-based immunotherapy. Mice were
given drinking water supplemented with 0.13 mg/ml CTX from
day 3 till day 10 and day 14 till day 21. Tumor-lysate-pulsed DCs
were given at day 12. Survival significantly improved when CTX
and DC-based immunotherapy were combined compared to DC-
based immunotherapy (P = .0035) or CTX administration alone
(P = .0056). Each group contained 8 mice.
into three groups, receiving low-dose CTX before (day 3
till 10) or after (day 14 till 21) immunotherapy or long-
term CTX (day 3 till 10 and day 14 till 21). Mice were
treated with DC-immunotherapy on day 12. No significant
differences were found between the groups (before [P =
.37] , after treatment [P = .84]). However long-term CTX
administration may prolong the survival beneficial since no
side effects of this low dose were observed (Figure 5).
4. Discussion
Cancer immunotherapy attempts to harness the exquisite
power and specificity of the immune system to recognize
and destroy tumor cells or to prevent tumor recurrence.
The finding that some patients with malignant pleural
mesothelioma (MM) have tumors that regress spontaneously
[40–43] or respond to immunotherapy [44–48] suggests that
the immune system can generate antitumor reactivity under
specific circumstances [41, 49].
DCs are extremely potent antigen-presenting cells spe-
cialized in inducing activation and proliferation of lympho-
cytes, which are essential for tumor killing [50]. Patient’s own
DCs can be used to present tumor-associated antigens and
thereby generate tumor-specific immunity [3, 4]. Previously
we used the mesothelioma mouse model to examine the
impact of dendritic cell immunotherapy [5]. For malignant
mesothelioma, as for most other cancer types, only a
few tumor-associated antigens (TAAs) are known. These
antigens are not expressed on the membranes of all tumors
and therefore less suitable for antigen source for DC pulsing.
Furthermore, none of these TAAs have been evaluated as
a source of peptides to pulse DC or in a cancer vaccine
trial. Tumor lysate priming strategies are advantageous in
providing the full antigenic repertoire of the tumor and,
particularly, unique individual tumor antigens, which will
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Figure 5: Long-period administration of CTX improves survival
compared to pre- or post-immunotherapy treatment. Mice were
divided into four groups (n = 6 per group) and inoculated with
a lethal dose of AB1 tumor cells on day 0. Mice received low-dose
CTX before (day 3 till 10) or after (day 14 till 21) immunotherapy
or metronomic dosed CTX (day 3 till 10 and day 14 till 21).
Groups 2, 3, and 4 were treated with DC-immunotherapy on day
12. Group 1 functioned as a tumor control group and did not
receive any treatment. Administration of metronomic dosed CTX
was not significantly better than CTX treatment before (P = .840)
or after (P = .454) immunotherapy. However, the combination
of CTX and immunotherapy was significantly better than no
treatment (CTX before immunotherapy compared to untreated
P = .0081, CTX after immunotherapy compared to untreated
P = .0147, metronomic dosed CTX and immunotherapy compared
to untreated P = .0018).
theoretically decrease the ability of tumors to evade the
immune response by downregulation of a single antigen.
Therefore, DCs were pulsed with autologous total tumor
lysate fractions prepared by freeze thawing and sonication
of AB1 tumor cells. Mice receiving tumor lysate-loaded DCs
developed a protective antitumor immunity when animals
were vaccinated before tumor inoculation. They showed no
signs of tumor growth even after 3 months and after repeated
injection of tumor cells (2nd tumor challenge). MM had
a better outcome when DCs were injected early in tumor
development indicating that tumor load played an important
role in survival.
There are multiple levels to explain the limited benefit
from DC vaccinations in mice with high tumor load. It has
been suggested that immune suppression by tumor-derived
factors is one of the main reasons for immunotherapy
failure in general [7, 51]. Tumors escape immune recognition
by attracting immune suppressive cells like Treg cells and
myeloid-derived suppressor cells. Others and we have shown
that mesothelioma cells are potent sources of a number
of cytokines (e.g., IL-6, IL-8, VEGF, GRO, and RANTES)
that might directly suppress immune activating cells, like
DCs and/or recruit suppressive cells and thereby abolish an
efficient immune response [8]. It has become evident that
while protecting the host against cancer development, the
immune cells also promote the emergence of tumors with
reduced immunogenicity leading to a complex interplay of
tumor growth and tumor regression mechanisms.
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Like in human mesothelioma biopsies, a growing
AB1 tumor in vivo contains significant amounts of
CD4+CD25+Foxp3+ regulatory Tcells, which were previously
shown to promote tumor progression in other cancer
models. Exact mechanisms are not yet fully understood;
however one of the mechanisms by which Tregs can abolish
the effectiveness of immunotherapy may be by their capacity
to produce granzyme B. This can lead to killing of cytotoxic
T cells [52–54]. Depletion of Tregs by using a blocking anti-
CD25 antibody (PC61), capable of specifically binding to the
IL-2 receptor α-chain, led to an increased survival in mice;
however, this depleting antibody is not suitable for human
clinical use. Cyclophosphamide (CTX) is an alkylating
cytotoxic cancer drug that, depending on its dose and timing
of administration, has been used as a chemotherapeutic and
disease-modifying agent or to enhance immune responses
[14, 26, 27, 55–57]. Reports dating from the 1980s have
shown that under some conditions low-dose CTX can poten-
tiate antitumor immunity in mouse models [55]. Recently it
has been suggested that this effect is caused by the depletion
of Tregs [39]. Reductions in the amount of Tregs by using
CTX were also found in mesothelioma [28]. In addition, Van
der Most et al. showed that the combination of CTX and
gemcitabine eradicates established murine mesothelioma
whereas single treatment with gemcitabine did not lead
to total tumor regression [29]. However the benefit of
combining Treg depletion with DC-based immunotherapy
for mesothelioma was not established till now.
CD4+CD25+Foxp3+ regulatory T cells comprise between
5 and 10% of the total CD4+ population in the blood of mice,
and are important in controlling tolerance to self-antigens
and thereby maintain immune system homeostasis [54, 58].
We found that the prevalence of Tregs increases in tumor-
bearing mice in the tumor, peripheral blood, and lymph
nodes (Figures 1 and 3) as compared with normal controls.
Prolonged, lower-dose (“metronomic”) CTX inhibits the rise
of Tregs (Figure 3). This effect augments the efficacy of
dendritic cell-based immunotherapy (Figures 4 and 5). DC-
based immunotherapy leads to an increase in survival that is
further improved by depleting Treg cells.
5. Conclusion
We found that CTX is an applicable agent to reduce the
proportion of Tregs in tumor-bearing mice. In addition, we
showed that combining CTX and DC-based immunotherapy
significantly prolongs the mean and overall survival in
murine model for mesothelioma. We anticipate that CTX
allows the host immune system to overcome the immuno-
suppressive mechanisms of Tregs, thereby allowing for a
more complete and robust antitumor immune response
initiated by DC-vaccination that is paramount to eliminate
the tumor in vivo. Our findings suggest that CTX may also
potentiate the immunogenicity of DC-immunotherapy in
mesothelioma patients. In fact, these findings now form
the basis of a new trial aiming the depletion of Tregs by
CTX in combination with DC-based immunotherapy as
a multimodality treatment in mesothelioma patients after
chemotherapy.
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CTX: Cyclophosphamide
MM: Malignant mesothelioma
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